Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amotz Shemi

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Nucleic Acids Research|March 10, 2018
Ammonium and arsenic trioxide are potent facilitators of oligonucleotide function when delivered by gymnosisXiaowei Zhang, Daniela Castanotto, Xueli Liu, et al.
Oncotarget|September 30, 2015
Multistep, effective drug distribution within solid tumorsAmotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai, et al.
Toxicologic Pathology|May 6, 2016
Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer TherapyYuval Ramot, Shay Rotkopf, Rachel Malka Gabai, et al.
Oncotarget|May 27, 2015
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patientsTalia Golan, Elina Zorde Khvalevsky, Ayala Hubert, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2013
Mutant KRAS is a druggable target for pancreatic cancerElina Zorde Khvalevsky, Racheli Gabai, Itzhak Haim Rachmut, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Nucleic Acids Research|March 10, 2018
Ammonium and arsenic trioxide are potent facilitators of oligonucleotide function when delivered by gymnosisXiaowei Zhang, Daniela Castanotto, Xueli Liu, et al.
Oncotarget|September 30, 2015
Multistep, effective drug distribution within solid tumorsAmotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai, et al.
Toxicologic Pathology|May 6, 2016
Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer TherapyYuval Ramot, Shay Rotkopf, Rachel Malka Gabai, et al.
Oncotarget|May 27, 2015
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patientsTalia Golan, Elina Zorde Khvalevsky, Ayala Hubert, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2013
Mutant KRAS is a druggable target for pancreatic cancerElina Zorde Khvalevsky, Racheli Gabai, Itzhak Haim Rachmut, et al.
Pageof 1